Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › IL-2

IL-2

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of IL-2

13 trials tracked of IL-2: 1 in phase 3 or 4.

13Trials tracked
1Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 1 Phase 2 10 Phase 1 2
  1. Phase 4 Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment Completed
  2. Phase 2 In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis Completed
  3. Phase 2 Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer Completed
  4. Phase 2 Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC) Completed
  5. Phase 2 Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer Completed
  6. Phase 2 High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer Completed
Show 7 more trials
  1. Phase 2 Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma Completed
  2. Phase 2 Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People Completed
  3. Phase 2 Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD Completed
  4. Phase 2 Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma Completed
  5. Phase 2 Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma Completed
  6. Phase 1 FT516 and IL2 With Enoblituzumab for Ovarian Cancer Completed
  7. Phase 1 Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC Completed

Showing the 13 most-cited and recently-updated of 13 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Immunocytokines offer improved safety profiles compared to systemic cytokine therapy in cancer treatment
Allergy & Immunology Sys. Review
Immunocytokines offer improved safety profiles compared to systemic cytokine therapy in cancer treatment Newer cancer treatments may offer safer options for patients
This narrative review examines immunocytokines including IL-2, IL-12, and TNF-alpha based constructs for cancer treatment. The authors concl…
Newer versions of immune-boosting drugs may offer a safer way to treat cancer by reducing the severe side effects of older therapies.
Frontiers Sep 29, 2026
Targeted cytokine delivery platforms in canine oncology provide data for human immuno-oncology dose selection
Allergy & Immunology Sys. Review
Targeted cytokine delivery platforms in canine oncology provide data for human immuno-oncology dose selection Cytokine Therapies Show Potential for Treating Canine Cancers
This mini review synthesizes evidence on targeted cytokine delivery platforms, such as IL-12 and IFN-beta, in dogs with various spontaneous …
New research explores how targeted cytokine delivery systems can treat various cancers in dogs and provide data for future human cancer trea…
Frontiers Jul 6, 2026
Review synthesizes Treg biology and NB-UVB, JAK inhibitors, IL-2 in vitiligo patients
Allergy & Immunology Sys. Review
Review synthesizes Treg biology and NB-UVB, JAK inhibitors, IL-2 in vitiligo patients Review shows immune cells may be off in vitiligo
This narrative review examines Treg biology and immunoregulatory functions alongside NB-UVB, JAK inhibitors, and low-dose IL-2 in vitiligo p…
A review finds immune cells that calm inflammation are fewer and less effective in people with vitiligo, suggesting a path for future treatm…
Frontiers May 18, 2026
Network meta-analysis compares biologics and targeted drugs for systemic lupus erythematosus efficacy and safety
Infectious Disease Meta-analysis
Network meta-analysis compares biologics and targeted drugs for systemic lupus erythematosus efficacy and safety New Lupus Treatments Show Stronger Results With Fewer Side Effects
This systematic review and network meta-analysis of 17,121 patients with systemic lupus erythematosus compared biologics and targeted small …
Certain new lupus drugs help more people feel better with fewer flare-ups, especially those struggling with rashes or joint pain that older …
Frontiers May 2, 2026
Systematic review examines IL-15-based immunotherapy for cancer with manageable toxicity profiles
Allergy & Immunology Sys. Review
Systematic review examines IL-15-based immunotherapy for cancer with manageable toxicity profiles New Immune Booster Could Help Cancer Fighters Last Longer
A systematic review evaluated IL-15-based cancer immunotherapy, including recombinant IL-15 and immunocytokines, for cancer treatment.
A new immune booster helps cancer fighters stay active longer, potentially making treatments for solid tumors and CAR-T therapy work far bet…
Frontiers Apr 16, 2026